CTRI/2022/06/043468已完成未知
A randomized open label two treatment two period two sequence crossover comparative bioavailability study of Single dose (0.6 mg) of Liraglutide 6 mg/ml solution for injection in pre-filled pen of Biocon Pharma Limited India with Single dose (0.6 mg) of Victoza�® (liraglutide) 6 mg/ml solution for injection in pre-filled pen of Novo Nordisk A/S Denmark administered subcutaneously in healthy adult human subjects under fasting condition - LIRAPK
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1. Healthy adult male and/or female subjects within the age range of 18 to 45 years [both inclusive]
- •2. Weight not less than 50 kg for male and 45 kg for female and BMI 18.50 to 30.00 kg/m2 [both inclusive].
- •3. Willingness and capability to provide written informed consent to participate in the study and agree to comply with the protocol requirements.
- •4. Subject should be literate.
- •5. Subjects who have no evidence of any underlying disease conditions during screening performed within 21 days prior to first dosing.
- •6. Subjects whose screening laboratory values, vital signs, Oxygen saturation (SpO2 %), ECG and Chest-X ray are within the normal limits; or if not, considered by physician/principal investigator to be of no clinical significance.
- •7. Subjects with normal levels of HbA1c (glycosylated haemoglobin).
- •8. Subjects should be non-alcoholic, non-smoker [defined as someone who has stopped smoking for a year before the date of screening] and should not be consuming tobacco containing products.
- •9. Male subjects must be using condom and another effective method of birth control if they are having sex with a woman of child-bearing potential. These measures are required during the study and for at least three months after the last Liraglutide dose. Contraceptive usage requirement will be conveyed during the inform consent process.
- •10. Female subjects of childbearing potential must be using two acceptable methods of contraception, (e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.). These measures are required during the study and for at least three months after the last Liraglutide dose and contraceptive usage requirement will be conveyed during the inform consent process.
- •11. Postmenopausal women for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy have been performed).
排除标准
- •1. Known history or presence of the following:
- •a) Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, ocular, endocrine (including diabetes), immunologic, dermatologic, venereal, neurological, musculoskeletal or psychiatric disease/disorder.
- •b) Asthma, urticaria or other allergic reactions after taking any medication.
- •c) Alcohol dependence, alcohol abuse or drug abuse (marijuana [THC], cocaine, morphine, benzodiazepines, barbiturates and amphetamine) for past one year.
- •d) Serious non-healing wound/ulcer/bone fracture or recurrent mouth ulcers, stomatitis, oral mucositis.
- •2. Hypersensitivity or contraindication to Liraglutide, related chemical substances or to any of the excipients in the formulation.
- •3. Presence of dermatological abnormalities at the injection site before dosing.
- •4. History of thyroid diseases.
- •5. Use of Liraglutide or Exenatide within 3 months before enrolment in to the study.
- •6. Recurrent severe hypoglycemia (more than one episode within the past 12 months).
- •7. Hypoglycemia unawareness, or severe autonomic neuropathy.
- •8. Subjects with type 1 & 2 diabetes mellitus or diabetic ketoacidosis.
- •9. Subjects with inflammatory bowel disease and diabetic gastroparesis.
- •10. Personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.
- •11. History of pancreatitis, stones in gallbladder (gallstones).
- •12. History of increasing shortness of breath or trouble breathing (especially when lie down), swelling or fluid retention (especially in the feet, ankles or legs), an unusually fast increase in weight, unusual tiredness.
- •13. Any difficulty in accessibility of forearm veins for cannulation or blood sampling.
- •14. Consumption of xanthine containing products, or alcohol within 48 h prior to dosing.
- •15. Consumption of grapefruit or its products/juice within 7 days prior to dosing.
- •16. Found positive in breath alcohol test done during period I check-in and inability to abstain from alcohol till the end of the study.
- •17. Found positive in urine drug screening during period I check-in.
- •18. Found positive in HIV-1 and/or 2 and/or Hepatitis B and/or C tests during screening.
- •19. Any difficulty to take / while taking study formulation.
- •20. Refuse to abstain from food for at least 10 h prior to dosing and at least 4 h after dosing in each period.
- •21. Received any medication [including over-the-counter products] except for paracetamol, acetylsalicylic acid, contraceptives and vitamins (but including mega-dose vitamin therapy, as judged by the investigator) prior to 14 days of enrolment.
- •22. Use of enzyme-modifying drugs or herbal products within the 30 days prior to first dosing, or within a period of 5 half-lives of that agent, whichever is longer.
- •23. Donation of 500 mL or more blood within the 90 days prior to the first dose of study drug.
- •24. Subjects who have participated in another clinical study in the past 90 days prior to commencement of this study.
- •25. Pregnant females as determined by positive test for pregnancy at screening or during period I check-in.
- •26. Lactating females.
- •27. Any other condition that precludes adequate understanding, cooperation, and compliance with study procedures or any condition that could pose a risk t
研究者
相似试验
已完成
不适用
Study on Leuprolide Acetate depot suspension 7.5 mg of sun pharmaceutical industries Limited in prostate cancer patients to compare the blood levels of test product with that of reference productCTRI/2018/06/014606Sun Pharmaceutical Industries Ltd India21
进行中（未招募）
不适用
Two way crossover steady state pharmacokinetics and bioavailability study of Xykaa 1000 mg Extend release tabletCTRI/2015/01/005468Troikaa Pharmaceuticals Ltd18
已完成
1 期
A clinical trial to study and compare the pharmacokinetic and pharmacodynamic effects of two dry powder inhaler devices, test and reference containing Salmeterol 25mcg and fluticasone propionate 250mcg with salmeterol 50mcg and fluticasone propionate 500mcg in patients with severe asthma.CTRI/2013/08/003878Sun Pharma Advanced Research Company Ltd24
Unknown
Unknown
This is a comparative drug concentration assessment study of Aripiprazole 400 mg Injection in patients with schizophrenia.CTRI/2023/05/052569PLIVA Croatia Ltd
招募中
不适用
Bioequivalence study of Sitagliptin 50mg tablet of Alborzdarou Pharm Co., IRA.IRCT20190706044111N4Alborzdarou Pharm. Co.24